#rheumtwitter #sarcoid #rheumatology #Deucravacitinib
---
RT @SteZhao
🚨TYK2 inhibition is associated with reduced risk of sarcoidosis.
Suggesting that #TYK2 inhibitors eg #deucravacitinib - trialed for psoriasis/PsA - may be worth testing for treatment of #sarcoidosis - chronic condition for which few drugs are approved.
https://ard.bmj.com/content/82/3/445
https://twitter.com/SteZhao/status/1639640115092893696
#RheumTwitter #sarcoid #rheumatology #deucravacitinib #tyk2 #sarcoidosis
#Takeda Bets $4B Upfront on Nimbus' #TYK2 Inhibitor | BioSpace
https://www.biospace.com/article/takeda-drops-6b-for-nimbus-therapeutics-tyk2-autoimmune-drug/ #pharma #immunology
#takeda #tyk2 #pharma #immunology
#Takeda Bets $4B Upfront on Nimbus' #TYK2 Inhibitor | BioSpace
https://www.biospace.com/article/takeda-drops-6b-for-nimbus-therapeutics-tyk2-autoimmune-drug/ #pharma #immunology
#takeda #tyk2 #pharma #immunology